Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15208119 | 1.00 | AAK1 (0.35) | AAK1HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL578889 | 1.00 | AAK1 (0.35) | AAK1HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL27685428 | 0.98 | AAK1 (0.34) | AAK1HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL7101631 | 0.92 | HDAC6 (0.37) | AAK1HDAC6HDAC1HDAC2MMP13 | |
| SCHEMBL74866 | 0.84 | AAK1 (0.36) | AAK1HDAC6HDAC1HDAC2MMP13 | |
| SCHEMBL2837457 | 0.83 | HDAC6 (0.35) | HDAC6HDAC1HDAC2L3MBTL1CTSK | |
| SCHEMBL31716095 | 0.81 | L3MBTL1 (0.38) | AAK1HDAC6L3MBTL1CA1CA2 | |
| SCHEMBL31716325 | 0.81 | ALDH1A1 (0.35) | AAK1HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL25165441 | 0.80 | HDAC6 (0.33) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL2968992 | 0.80 | AAK1 (0.36) | AAK1HDAC6HDAC1HDAC2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703802-B2 | Process for the preparation of aryl substituted olefinic amines | TARGACEPT, INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-20130225827-A1 | New Process for the Preparation of Aryl Substituted Olefinic Amines | TARGACEPT, INC. (US) | 2013-08-29 | — | — | US | claimed |
| CN-103180277-A | New process for the preparation of aryl substituted olefinic amines | TARGACEPT INC | 2013-06-26 | — | — | CN | claimed |
| EP-2253616-A1 | Process for the preparation of compounds capable of activating cholinergic receptors | Targacept, Inc. (US) | 2010-11-24 | — | — | EP | claimed |
| US-20100204481-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-08-12 | — | — | US | claimed |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-05-13 | — | — | US | claimed |
| EP-1814852-B1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | CATALYST BIOSCIENCES INC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150313883-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT INC (US) | 2015-11-05 | — | — | US | disclosed |
| US-9107915-B2 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150119378-A1 | AZETIDINYLOXY-, PYRROLIDINYLOXY-, AND PIPERIDINYLOXY-SUBSTITUTED METANICOTINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT INC (US) | 2015-04-30 | — | — | US | disclosed |
| US-20140288132-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT INC (US) | 2014-09-25 | — | — | US | disclosed |
| US-8778978-B2 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8703802-B2 | Process for the preparation of aryl substituted olefinic amines | TARGACEPT, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| WO-2000075110-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. (US) | 2000-12-14 | — | — | WO | disclosed |
| EP-1056458-A1 | METHOD FOR THE TREATMENT OF PAIN, INCLUDING CHRONIC AND FEMALE SPECIFIC PAIN | Wake Forest University (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-2000062767-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION | TARGACEPT, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
| EP-1042274-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000023418-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-04-27 | — | — | WO | disclosed |
| WO-1999065876-A1 | ARYL SUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999043322-A1 | METHOD FOR THE TREATMENT OF PAIN, INCLUDING CHRONIC AND FEMALE SPECIFIC PAIN | WAKE FOREST UNIVERSITY (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225827-A1 | New Process for the Preparation of Aryl Substituted Olefinic Amines | PNMT, MAOB, AOC2 | AAK1 1704/4885HDAC6 1826/4885HDAC1 2178/4885 |
| US-20150313883-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | AAK1 4035/4885HDAC6 828/4885HDAC1 1454/4885 |
| US-20100204481-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRNA4, CHRNB4, CHRM4 | AAK1 2507/4885HDAC6 1918/4885HDAC1 1214/4885 |
| US-20140288132-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | AAK1 4035/4885HDAC6 828/4885HDAC1 1454/4885 |
| US-20150119378-A1 | AZETIDINYLOXY-, PYRROLIDINYLOXY-, AND PIPERIDINYLOXY-SUBSTITUTED METANICOTINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA5, CHRNA2, CHRNB2 | AAK1 1874/4885HDAC6 356/4885HDAC1 829/4885 |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRM3, CHRM5, CHRM4 | AAK1 3613/4885HDAC6 1198/4885HDAC1 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.